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Chronic microinflammation increases cardiovascular
morbidity in chronic hemodialysis (HD) patients. Previously
published studies are controversial with respect to acute
effects of HD treatment on up- or downregulation of cytokine
protein levels. Twenty-nine chronic HD patients were
hemodialysed for 4 h with a 4008 dialyser using high-flux
membranes. Patients were separated into a low (up to 1 mg/
dl) and a high (1.1 to 5.5 mg/dl) C-reactive protein (CRP)
group. Blood was drawn before HD and 240 min after
initiation of HD. Acute changes of transcript levels encoding
pro- and anti-inflammatory mediators were analyzed in
RNA stabilized immediately from blood leukocytes using
microarray analysis (n¼ 1) and quantitative real-time
polymerase chain reaction (PCR) (Light Cycler) (n¼ 29). In
both patient groups, HD treatment significantly increased the
transcript levels of several pro-inflammatory cytokines, such
as tumor necrosis factor alpha and interleukin-8 (IL-8), and
chemokine receptors such as C-X-C chemokine receptor
type 4, C-C chemokine receptor type 7, and the fractakine
receptor CX3C chemokine receptor 1. In the low CRP group,
the increase of transcript levels for anti-inflammatory
IL-1-receptor antagonist and of the receptor for the
anti-inflammatory cytokines IL-10 and interferon gamma was
significantly more pronounced than in the high CRP group.
Subgroup analysis revealed no difference between diabetic
vs non-diabetic patients. These observations point towards
a marked influence of a routine hemodialysis treatment on
transcription in leukocytes of pro- and anti-inflammatory
cytokines and receptors relevant for microinflammation.
Diminished upregulation of receptors for anti-inflammatory
factors in HD patients with high CRP levels could contribute
to enhanced microinflammation in those patients.
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In comparison to healthy controls, chronic hemodialysis
(HD) patients show elevated cytokine levels maintaining
chronic microinflammation, which in turn increases cardio-
vascular morbidity in those patients.1 Earlier studies
demonstrated elevated plasma cytokine levels in HD patients
dialyzed with regenerated cellulose membranes2 or with more
biocompatible membranes like polysulfone or polyamide.3
Besides the major pro-inflammatory cytokines IL-1 and
tumor necrosis factor alpha (TNF-a), plasma levels of IL-62,4
and IL-185 were reported to be higher in HD patients than in
healthy controls. The enhanced plasma levels of cytokines are
caused by multiple factors, including exogenous factors such
as dialyzate pyrogens/short bacterial DNA fragments, bio-
incompatibility of dialyzer membranes/artificial shunt mate-
rials, or endogenous factors such as local or systemic
infections, complement activation, oxidative burst, activation
of the renin–angiotensin–aldosterone-system and nuclear
factor kappa B system, loss of renal excretion of cytokines,
and an imbalance of tissue helper type 1/tissue helper type 2
cells owing to uremic toxins.6–8 An altered cytokine profile in
HD patients is proven to influence the prognosis of the
patients. For instance, increased levels of the circulating pro-
inflammatory cytokines IL-1, TNF-a, IL-6, and IL-13 were
shown to be associated with enhanced mortality of HD
patients.9
However, controversial studies have been published with
respect to acute effects of HD on the regulation of cytokines.
Although cytokines are relevant for microinflammation,
several studies have shown variable results of changes of
cytokine levels during HD sessions (for a review, see Jacobs
et al.8). Inconsistent results have been published for the main
pro-inflammatory players like IL-1b, TNF-a, IL-6, and
IL-18.10–15. Changes of cytokine levels during HD are difficult
to capture at early time points. Other factors may modify the
plasma cytokine concentrations at later time points. Plasma
concentrations may lag behind stimulation of cytokine
formation in circulating leukocytes. Part of the cytokine
proteins could only be detected in mononuclear cells, which
are preincubated with strong inductors like lipopolysacchar-
ides or phorbol 12-myristate 13-acetate.8 Moreover, in vivo
determination of cytokine plasma concentrations is compli-
cated by circulating soluble receptors.16
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The first event of the microinflammatory cascade is the
intracellular transcriptional upregulation of cytokine mRNA
in circulating leukocytes. Semiquantitative polymerase chain
reaction (PCR) studies showed that peripheral blood mono-
nuclear cell exposure to cuprophane membranes led to
mRNA overexpression for IL-6, interleukin-8 (IL-8), and
monocyte chemotactic peptide-1.17 In contrast to these
results, high-flux noncomplement activating membranes
significantly reduced the dialysis-induced gene expression.17
To gain insight into the transcriptional profile of blood
leukocytes before and after hemodialysis, we performed
microarray analysis and subsequently confirmed these results
by quantitative real-time PCR. The aim of this study was to
identify and quantify alterations of transcript levels of pro-
inflammatory and anti-inflammatory mediators in blood
leukocytes during a standard 4-h HD treatment.
RESULTS
Patients
Patients (18 male; 11 female; mean age 65711 years) were
subjected to hemodialysis treatment for 42 months (mean
time: 52771 months). Patients with high C-reactive protein
(CRP) levels (2.771.3 mg/dl) and patients with low CRP
levels (0.470.4 mg/dl) were analyzed separately. Clinical
conditions of the groups are provided in Table 1.
In both CRP groups, patients with diabetes mellitus type II
(high: seven out of 11 vs low: eight out of 18, NS) were
included, the high CRP group had significantly more patients
with peripheral arterial occlusive disease compared to the low
CRP group (eight out of 11 vs five out of 18, Po0.05). Blood
leukocyte count was significantly higher in the high CRP group
(782372085/ml) than in the low CRP group (613771508/ml).
Patients of the two groups did not differ significantly from
each other in respect to age, time on hemodialysis, type of
dialyzer membranes used, or plasma concentrations of
hemoglobin, albumin, or total protein. Differential blood
count did not differ between measurements before HD and
after 60/120/240 min HD (n¼ 6, data not shown).
Microarray analysis
Leukocyte transcript levels of pro-inflammatory TNF-a
increased 3.6970.59-fold following a 4 h HD treatment, as
compared to pretreatment levels (Table 2). Microarray
analysis did not yield a significant increase of transcript
levels encoding the pro-inflammatory cytokines IL-1b
(1.1970.19) or IL-6 (no signal detectable), but revealed
increased transcript levels of IL-8 (1.7170.27) and, to a small
extent, of IL-18 (1.3370.22).
On the other hand, microarray analysis disclosed an
increase of transcript levels of several anti-inflammatory
mediators and receptors. According to microarray analysis,
HD treatment increased the transcript levels of the IL-1
receptor antagonist IL-1RN (2.4770.08) (Table 2), the IL-4
receptor (2.2470.08), the IL-10 receptor (2.0970.18), the
a- and b-chain of the interferon gamma (IFNg) receptor
(1.8870.03 and 1.8670.12, respectively), the CX3C chemo-
kine receptor 1 (CX3CR1) (2.6370.06), the C-X-C chemo-
kine receptor type 4 (CXCR4) (1.9870.07), and of the C-C
chemokine receptor type 7 (CCR7) (1.7370.17).
Quantitative real-time PCR
Transcript levels of pro-inflammatory cytokines. Including
all patients, the induction factor of TNF-a transcript levels to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
mRNA levels significantly increased by 1.7170.19 following
a 240 min HD treatment (Po0.05, Figure 1a). When patients
Table 1 | Patient characteristics
All patients
(n=29)
Low CRP group
(n=18)
High CRP group
(n=11)
Statistical analysis
(low/high)
Age (years) 65711 66713 6579 NS
Time on hemodialysis (months) 52771 52762 52786 NS
Dialyzer membranes (F60/F80) 26/3 16/2 10/1 NS
Diabetes mellitus (type II) 15/29 8/18 7/11 NS
Peripheral arterial occlusive disease 13/29 5/18 8/11 o0.05
Hemoglobin (g/dl) 11.671.2 11.771.3 11.371.0 NS
Leukocytes/ml 677771904 613771508 782372085 o0.05
CRP (mg/dl) 1.371.5 0.470.4 2.771.3 o0.01
Albumin (g/dl) 4.070.4 4.070.2 3.870.5 NS
Total protein (g/dl) 6.870.5 6.970.5 6.870.5 NS
CRP, C-reactive protein; NS, not significant.
Table 2 | Microarray data
Gene name Cy5/Cy3 ratioa
TNF-a 3.6970.59
IL-1b 1.1970.19
IL-8 1.7170.21
IL-18 1.3370.22
IL-1RN 2.4770.08
IL-4R 2.2470.08
IL-10R 2.0970.18
IFN-gR1 1.8870.03
CX3CR1 2.6270.06
CXCR4 1.9870.07
CCR7 1.7370.17
C3aR1 3.7970.05
C3aR1, complement component 3a receptor 1; CCR7, C-C chemokine receptor Type
7; CX3CR1, CX3C chemokine receptor 1; CXCR4, C-X-C chemokine receptor Type 4;
IFN-gR1, interferon-gamma-receptor; IL-1b, interleukin-1-beta; IL-4R, interleukin-4
receptor; IL-10R, interleukin-10 receptor; IL-18, interleukin-18; IL-1RN, interleukin-1
receptor antagonist; TNF-a, tumor necrosis factor-alpha.
aValues represent fold increase of upregulated gene after 4 h hemodialysis.
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were separated into a high and a low CRP group, TNF-a
levels were generally higher following HD in comparison to
levels obtained before HD; however, transcript levels were not
significantly different between the low/high CRP subgroup.
There was no correlation with CRP levels (Figure 1a:
r¼0.0065, NS). Similar results were observed with respect
to IL-1b transcript levels, which were slightly but significantly
increased (induction factor 1.2570.06) (Figure 1b). IL-1b
levels were not significantly correlated with CRP levels
(r¼0.15, NS). In contrast IL-8 transcript levels in blood
leukocytes were significantly increased after HD treatment.
Strongly elevated levels of IL-8 transcripts after HD were
observed in the pooled patient group (induction fac-
tor3.2170.46, Po0.01) as well as the CRP subgroups. Values
of both the complete patient pool and subgroups reached
statistical significance (high CRP group: 2.5270.38, Po0.01;
low CRP group: 3.6470.69, Po0.01) (Figure 1c). The
observed differences within the subgroups (high CRP vs low
CRP; diabetic vs non-diabetic patients) were not significant.
No significant correlation was observed between IL-8 trans-
cript levels and CRP values (r¼0.15, NS). Interestingly,
no alteration of IL-18 transcript levels could be found after
HD treatment (Figure 1d). Time course experiments (n¼ 6)
with additional time points at 60 and 120 min revealed
an induction of pro-inflammatory cytokines directly at the
second time point (60 min). The values at 60 and 120 min
were not significantly different from the final time point at
240 min (data not shown).
Taken together, HD treatment significantly increased
transcript levels of several pro-inflammatory cytokines such
as TNF-a, IL1-b, and IL-8, but there was no correlation of
enhanced transcript levels and CRP values. Comparable
induction factors were found in diabetic and non-diabetic
patients.
Transcript levels of anti-inflammatory cytokines and recep-
tors. HD treatment was followed by a significant increase of
transcript levels of IL-1RN in the pooled patient group
(1.3470.07, Po0.01) (Figure 2a). The increase of IL-1RN
transcript levels was significantly more pronounced in the
low CRP patient group than in the high CRP patient group
(1.4670.08 vs 1.1370.09; Po0.05). In contrast to the pro-
inflammatory cytokine transcripts, we calculated a significant
correlation for IL-1RN between induction factor and CRP
level (r¼0.49, Po0.01 – Figure 2a). Similarly, HD induced
an increase of mRNA levels encoding the anti-inflammatory
cytokine IL-4 receptor. This effect was stronger in the low
CRP group (1.5370.18; Po0.01 compared to prior HD)
than in the high CRP group (1.1770,15; NS), and reached
statistical significance in the pooled whole group (1.4070.13;
Po0.01 – Figure 2b). The increase of IL-4R levels correlated
with CRP levels and reached similar values as IL-1RN levels
(r¼0.37, Po0.05). A highly significant increase of trans-
cript levels encoding the receptor for the anti-inflammatory
cytokine IL-10 (IL-10R) was detected only in the low CRP
group (1.5170.14, Po0.01 – Figure 2c) following HD
treatment. Increase of IL-10R transcript levels was signifi-
cantly higher in the low CRP patient group compared to the
high CRP patient group (1.5170.14 vs 1.0770.09; Po0.05).
IL-10R transcript levels and CRP levels were significantly
correlated (r¼0.39, Po0.05).
Transcript levels for the interferon gamma receptor 1
(IFNg-R1) increased significantly only in the low CRP patient
group (1.5170.14, Po0.01 – Figure 2d), but not in the high
CRP patient group (1.0770.09, NS). The induction was
stronger in the non-diabetic group, but did not reach
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Figure 1 | Pro-inflammatory cytokine transcript levels in blood
leukocytes derived from chronic HD patients (n¼ 29) by
quantitative real-time PCR. Induction factors were calculated
as ratio between target genes and house keeping gene GAPDH
compared with transcript levels before HD from all patients (n¼ 29),
the high CRP group (n¼ 11), and the low CRP group (n¼ 18). Diabetic
patients (n¼ 15) were also divided into high CRP (n¼ 7) and low
CRP group (n¼ 8), and non-diabetic patients (n¼ 14) similarly in
a high-CRP (n¼ 4) and low-CRP (n¼ 10) group. Values are shown
as mean 7s.e.m. #Significant difference between high and low CRP
group (Po0.05). *Significant induction vs transcript levels before
HD (Po0.05). Correlation curves show induction factor of the
target gene/GAPDH versus CRP levels. (a) TNFa, (b) IL-1b, (c) IL-8,
and (d) IL-18.
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statistical significance in comparison to diabetic patients.
Similar to the above-mentioned anti-inflammatory factors,
IFNg-R1 transcript levels were significantly correlated with
CRP levels (r¼0.39, Po0.05 – Figure 2d).
Taken together, only the low CRP patient group showed
significant increases of transcript levels for several anti-
inflammatory cytokines and/or receptors such as IL1-RN,
IL-4R, IL-10R, and the IFNg-R1. The induction factors
correlated significantly with measured CRP values. There
were no significant differences between diabetic vs non-
diabetic patients.
Transcript levels of chemokine receptors. HD treatment led
to a significant increase of CX3CR1 transcript levels in the
pooled patient group (1.4670.11; Po0.01) and the low CRP
group (1.5870.14, Po0.01), but not in the high CRP group
(1.2570.18; NS – Figure 3a). There was no significant
difference between the groups. The correlation between the
induction factor and CRP showed a tendency which was,
2.0
1.8
1.6
1.4
1.2
1.0
In
du
ct
io
n 
fa
ct
or
 IL
-1
RN
/G
AP
DH 2.5
2.0
1.5
1.0
0.5In
du
ct
io
n 
fa
ct
or
 IL
-1
RN
/G
AP
DH
a
2.2
2.0
1.8
1.6
1.4
1.2
1.0
In
du
ct
io
n 
fa
ct
or
 IL
-4
R/
G
AP
DH 3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0In
du
ct
io
n 
fa
ct
or
 IL
-4
R/
G
AP
DH
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0In
du
ct
io
n 
fa
ct
or
 IL
-1
0R
/G
AP
DH
b
2.2
2.0
1.8
1.6
1.4
1.2
1.0
In
du
ct
io
n 
fa
ct
or
 IL
-1
0R
/G
AP
DH
c
2.6
2.4
2.2
2.0
1.8
1.6
1.4
1.2
1.0
In
du
ct
io
n 
fa
ct
or
 IF
N-
R
/G
AP
DH 5
4
3
2
1
0In
du
ct
io
n 
fa
ct
or
 IF
N-
R
1/
G
AP
DH
d
∑ High+low CRP
High CRP
Low CRP
∑ High+low CRP
High CRP
Low CRP
∑ High+low CRP
High CRP
Low CRP
∑ High+low CRP
High CRP
Low CRP
All patients Diabetic Non-diabetic
All patients Diabetic Non-diabetic
All patients Diabetic Non-diabetic
All patients Diabetic Non-diabetic
IL-1RN
IL-4R
IL-10R
IFN-R1
1 2 3 4 5 60
CRP (mg/dl)
1 2 3 4 5 60
CRP (mg/dl)
1 2 3 4 5 60
CRP (mg/dl)
1 2 3 4 5 6
CRP (mg/dl)
*
*
*
*
*
*
*
*
*
*
*
*
* *
*
*
*
*
*
*
#
#
#
Figure 2 | Anti-inflammatory cytokine transcript levels in blood
leukocytes derived from chronic HD patients (n¼ 29) by
quantitative real-time PCR. Induction factors were calculated as
ratio between target genes and house keeping gene GAPDH
compared with transcript levels before HD from all patients (n¼ 29),
the high CRP group (n¼ 11) and the low CRP group (n¼ 18). Diabetic
patients (n¼ 15) were also divided in a high CRP (n¼ 7) and low CRP
group (n¼ 8) as were non-diabetic patients (n¼ 14; high CRP, n¼ 4;
low CRP, n¼ 10). Values are shown as mean7s.e.m. #Significant
difference between high and low CRP group (Po0.05). *Significant
induction vs transcript levels before HD (Po0.05). Correlation curves
show induction factor of the target gene/GAPDH vs CRP levels.
(a) IL-1RN, (b) IL-4R, (c) IL-10R, and (d) IFN-gR1.
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Figure 3 | Transcript levels of chemokine receptors and C3aR
in blood leukocytes derived from chronic HD patients (n¼ 29)
by quantitative real-time PCR. Induction factors were calculated
as ratio between target genes and house keeping gene GAPDH
compared with transcript levels before HD from all patients (n¼ 29),
the high CRP group (n¼ 11) and the low CRP group (n¼ 18). Diabetic
patients (n¼ 15) were also divided into high CRP (n¼ 7) and low CRP
groups (n¼ 8) as were non-diabetic patients (n¼ 14; high CRP, n¼ 4;
low CRP, n¼ 10). Values are shown as mean7s.e.m. #Significant
difference between high and low CRP group (Po0.05). *Significant
induction vs transcript levels before HD (Po0.05). Correlation curves
show induction factor of the target gene/GAPDH vs CRP levels.
(a) CX3CR1, (b) CXCR4, (c) CCR7, and (d) C3aR.
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however, not significant (r¼ –0.35, Po0.06). We found
similar results for CXCR4. A significant increase of CXCR4
transcript levels following HD treatment was observed in the
pooled group (1.4670.10; Po0.01) and in the low CRP
group (1.5870.12; Po0.01), but not in the high CRP group
(1.2670.16; NS – Figure 3b). The correlation with CRP levels
was not significant (r¼0.28, NS). For CCR7, HD treatment
significantly increased transcript levels in the pooled, the high
CRP, and the low CRP patient group (1.5670.12, Po0.01;
1.2570.09, Po0.05; 1.7470.17, Po0.01 – Figure 3c). The
increase of CCR7 transcript levels was significantly more
pronounced in the low CRP patient group, than in the high
CRP patient group. The correlation with CRP levels, however,
was not significant (r¼0.28, NS).
Transcript levels of the complement 3a receptor. It is well
established that HD leads to an induction of the complement
system. Microarray analysis and real-time PCR disclosed
indeed significantly increased transcript levels of the C3a
receptor (C3aR) in the pooled, the high, and the low CRP
group (1.8270.22, Po0.01; 1.970.37, Po0.05, and
1.7770.27, Po0.05 – Figure 3d). No significant difference
was observed between high and low CRP groups, and the
correlation between the induction index and CRP was not
significant (r¼0.13, NS).
DISCUSSION
Chronic microinflammation leads to a higher cardiovascular
morbidity in chronic HD patients, but controversial studies
are published with respect to acute effects of HD treatment
on up- or downregulation of cytokine protein expression. To
our knowledge, the present report is the first description of a
quantitative analysis of the inflammatory gene expression
profile in blood leukocytes before and after HD treatment
without external stimulation of cells with lipopolysaccharides
or phorbol 12-myristate 13-acetate. For reliable quantifica-
tion of transcript levels in blood leukocytes, an RNA-
stabilizing system was required. In our experiments, total
RNA of blood leukocytes was immediately stabilized and
extracted using the PaxGene System (Qiagen, Hilden,
Germany). With this technique, we obtained sufficient
amounts of RNA from leukocytes, and the cytokine profile
was ‘frozen’ to prevent a time/sample bias.
In both CRP subgroups, we included diabetic patients
(seven vs eight patients with type II diabetes). Chronic
subclinical inflammation has been proposed as part of the
insulin-resistance syndrome in type II diabetes,18 but from
current available evidence it is not clear whether inflamma-
tory parameters are markers or mediators of insulin
resistance.19 As expected, analysis of patient characteristics
showed more patients in the high CRP group suffering from
peripheral arterial occlusive disease (eight out of 11, Po0.05)
compared to the low CRP group. Comparable to the CRP
values, blood leukocyte count was significantly higher in the
high CRP group than in the low CRP group.
In both patient groups, HD treatment significantly
increased transcript levels of several pro-inflammatory
cytokines such as TNF-a, IL-1b, and IL-8, as well as
chemokine receptors such as CXCR4, CCR7, and the
fractakine receptor CX3CR1. Analysis revealed that HD
significantly increases transcript levels of the pro-inflamma-
tory cytokines TNF-a and more strongly IL-8, irrespective of
the CRP levels. IL-18 gene expression was not significantly
induced by HD.
IL-8 is frequently classified as a pro-inflammatory
cytokine, but is actually a chemokine (CXCL8, which belongs
to the CXC family).20 It is the only chemokine significantly
modified by HD treatment in our study. Specifically, reactive
oxygen intermediates generated in the cellular microenviron-
ment upregulate IL-8 gene expression.21 Increased reactive
oxygen intermediate generation in chronic renal failure
patients is caused by endogenous and exogenous uremic
toxins, blood-dialyser membrane interaction, influx of
endotoxin fragments from dialyzate, and reaction to
catheters.22,23 It is likely that upregulation of reactive oxygen
intermediates during HD treatment is involved in the
induction of IL-8 synthesis.
An earlier study disclosed the induction of the chemokine
receptor CCR2 in uremic peripheral blood mononuclear cells
by semiquantitative PCR and protein measurements.24 Here,
we quantify the upregulation of further chemokine receptors
in HD patients. The chemokine receptor CCR7 transcript
levels increased during HD significantly more pronounced in
low CRP patients than in high CRP patients. CCR7 is known
to be expressed in activated T and B lymphocytes and
dendritic cells.25 Macrophage inflammatory protein-1 [b]
binds with high affinity to this chemokine receptor and the
recently defined CC chemokine 6-C-kine, also known as
secondary lymphoid-tissue chemokine (SLC), which has been
shown to be a specific agonist for CCR7.26 CXCR4 and
CX3CR1 transcript levels were significantly induced only in
the pooled and in the low CRP group of patients. Mice
lacking the CXCR4 gene exhibit impaired B lymphopoiesis,
myelopoiesis, hematopoiesis, and deranged cerebellar neuron
migration.27 The fractalkine receptor (CX3CR1) transduces
signals through G proteins that increase integrin binding to
its ligands.28 Fractalkine (CX3CL1) is a unique chemokine
that functions not only as a chemoattractant but also as an
adhesion molecule and is induced by IFNg or TNF-a.29 We
assume that upregulation of these chemokine receptors
during HD treatment renders the cells more susceptible to
the respective chemokines, which could contribute to the
development of microinflammation.
HD also leads to induction of the complement system.1
Modern biocompatible membranes such as polyacrylonitrile
or polysulfone are associated with diminished activation of
the complement system/neutropenia.30 Here, we show that
the use of polysulfone high-flux dialyzer membranes
significantly induces the transcription of the receptor for
anaphylatoxin C3a in blood leukocytes. This induction is not
related to CRP levels.
The most remarkable difference in gene expression bet-
ween both CRP groups was observed when anti-inflammatory
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factors were quantified. In the low CRP group, transcript
expression of the IL1-receptor antagonist (IL-1RN), the
receptor for the anti-inflammatory cytokines IL-4 and IL-10
as well as the receptor for IFNg seemed to be more effectively
induced by HD treatment than in the high CRP group.
Subgroup analysis revealed for all examined molecules/
receptors no significant difference between diabetic vs non-
diabetic patients.
IL-4 has a pivotal role in suppression of IL-2 activation
pathways at the level of signal transduction.31 In addition,
IL-4 possesses the ability to suppress gene expression and
synthesis of IL-1, TNF-a, and IFNg32 and to increase the
expression of IL-1RN.32 Likewise, IL-10 also represents a
tissue helper type 2 cytokine, which was termed cytokine
synthesis inhibitory factor, because it suppresses the synthesis
of inflammatory cytokines.33 In HD patients, a protective
role of IL-10 against systemic inflammation was shown.34
Increased expression of the receptors for anti-inflammatory
cytokines such as IL-4 and IL-10 could render the cells more
sensitive for these anti-inflammatory factors.
Detection of acute cytokine changes on the protein level in
HD patients is compromised by the short half-life and the
low plasma concentrations of most cytokines, as well as a
sample/time bias which influences the results of enzyme-
linked immunosorbent assay protein detection. In addition,
the time range of 4 h standard HD treatment is probably too
short for measurement of effects on the protein level.
Accordingly, some cytokine proteins could be detected only
in mononuclear cells which are preincubated with strong
external inductors like lipopolysaccharides or phorbol 12-
myristate 13-acetate.35
We show in this report that acute effects of HD treatment
on cytokine and chemokine transcription in blood leukocytes
can be determined by microarray analysis and subsequent
quantification using Light Cycler PCR after RNA stabilization
without (external) stimulation of the leukocytes. It should be
kept in mind, although, that transcription of cytokines does
not necessarily reflect the respective cellular protein release.16
The diminished upregulation of receptors for anti-inflam-
matory factors in HD patients with high CRP levels could
contribute to enhanced microinflammation in those patients.
The present study reveals that HD patients with low CRP
levels are probably better protected against microinflamma-
tion than HD patients with high CRP levels, as the balance
between pro- and anti-inflammatory cytokines and receptors
is more favorable in patients with low CRP levels than in
patients with high CRP levels.
MATERIALS AND METHODS
Patients
Twenty-nine stable HD patients (18 male; 11 female; mean age
65711 years) from one dialysis centre were included in this study.
One patient was excluded during the course of the study owing to an
unclear rise of CRP levels (45.5 mg/dl). Patients were divided in
two groups: a low CRP group (CRP levels between 0.0 and 1.0 mg/
dl, n¼ 18), and a high CRP group (CRP levels between 1.1 and
5.5 mg/dl, n¼ 11). For subgroup analysis, diabetic patients (n¼ 15)
were also divided into high CRP (n¼ 7) and low CRP groups
(n¼ 8). In the non-diabetic group (n¼ 14), four patients had high
CRP levels, 10 patients low CRP levels. Causes of renal insufficiency
were diabetic nephropathy (n¼ 15), chronic glomerulonephritis
(n¼ 3), vasculitis (n¼ 3), hereditary renal diseases (n¼ 3), and
others (n¼ 5). For details of patient characteristics, see Table 1.
All patients were hemodialyzed using a Fresenius 4008 dialysis
machine (Fresenius Medical Care, Bad Homburg, Germany)
containing a diasafe device for water pureness and using polysulfone
high-flux dialyzer membranes (F60/F80 – 26/3 patients, Fresenius
Medical Care, Bad Homburg, Germany). Bicarbonate dialyzate was
used throughout. Blood samples were drawn at 0 and 240 min of the
4 h HD sessions, and in addition at 60 and 120 min for time course
examinations. Differential blood count, CRP, albumin, and total
protein were measured using standard methods at our central
laboratory unit.
Exclusion criteria were severe comorbidities (e.g., malignancy,
active allergies), CRP 45.5 mg/dl, and active infections as indicated
by fever 4381C. All patients gave informed consent, and the study
was approved by the Ethic committee of the University of Tu¨bingen.
Pax gene RNA isolation and cDNA transcription
For the exact quantification of transcript levels, an RNA stabilizing
system was required. Total RNA of blood leukocytes was
immediately stabilized and extracted using the PaxGene System
(Qiagen, Hilden, Germany). Subsequently, 1 mg of total RNA was
reverse transcribed into cDNA utilizing the reverse transcription
system (Clontech Laboratories, Mountain View, CA, USA) with
oligo(dT) primers according to the manufacturer’s protocol.
Microarray analysis
Microarray analysis was performed using total RNA extracted from
blood leukocytes of one patient before and after a 4 h HD session
(treated sample). In total, 1 mg of total RNA was subjected to a
modified linear amplification protocol. The amplified RNA from the
treated sample (after 4 h HD session) was labelled by reverse
transcription with Cy5 fluorescence dye, and the amplified RNA
from the control (before HD) with Cy3, respectively. The labelled
samples were then hybridized to a human PIQOR Immunology
microarray including cDNAs from 1064 immunologically relevant
genes (Memorec Biotec GmbH, Cologne, Germany). Each cDNA is
spotted as quadruplicates on different positions of the array. Briefly,
signal quantification of hybridized microarray was performed with
the ScanArray 4000 Lite (Perkin Elmer Life Sciences, Rodgau,
Germany) and ImaGene software version 4.1 (BioDiscovery, Los
Angeles, CA, USA). The negative control for each array was
computed as the mean of signal intensity of four spots representing
hybridization of salmon sperm and four spots representing buffer
only. Normalized ratios are shown as Cy5 signal intensity divided by
Cy3 signal intensity of the respective gene.
Quantitative real-time PCR
Quantification of blood leukocyte mRNA expression by real-time
PCR with the LightCycler system (Roche Diagnostics, Mannheim,
Germany) has been described in detail elsewhere.36 Briefly, PCR
reactions for GAPDH, the pro-inflammatory cytokines TNFa/IL-1b/
IL-8/IL-18, the anti-inflammatory cascade with IL-1RN/IL-4R/IL-
10R/IFN-g R1, the chemokine receptors CX3CR1/CXCR4/CCR7,
and the complement receptor C3aR were performed in a final
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volume of 20 ml containing 2 ml cDNA, 2 ml primer mix (commercial
primer kits from Search LC, Heidelberg, Germany), 2 ml DNA
Master Sybr Green I mix (Roche Molecular Biochemicals,
Mannheim, Germany), and 14 ml diethyl pyrocarbonate-treated
water.
The target DNA was amplified during 35 cycles of 951C for 10 s,
681C for 10 s, and 721C for 16 s, each with a temperature transition
rate of 201C/s and a secondary target temperature of 581C with a
step size of 0.51C. Melting curve analysis confirmed the amplified
products, which were then separated on 1.5% agarose gels to
confirm the expected size. Induction factors were calculated as ratio
between target genes and house keeping gene GAPDH compared
with transcript levels before HD.
Statistical analysis
Data are expressed as means7s.e.m. Statistical analysis was performed
using parametric paired/non-paired t-tests for data with a normal
distribution. A value of Po0.05 was considered as significant. To
obtain the correlation curves, the induction factor of the target gene/
GAPDH was plotted against CRP levels (Software: Origin 6.0).
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